Journal
GASTROENTEROLOGY CLINICS OF NORTH AMERICA
Volume 42, Issue 1, Pages 155-+Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.gtc.2012.11.006
Keywords
Esophageal adenocarcinoma; Barrett's esophagus; Gastroesophageal reflux disease; Dysplasia; Biomarkers; Screening; Cost-effectiveness
Categories
Funding
- MRC [MC_U105365007] Funding Source: UKRI
- Medical Research Council [MC_U105365007] Funding Source: Medline
- Department of Health [NIHR-RP-02-12-011] Funding Source: Medline
- Medical Research Council [MC_U105365007] Funding Source: researchfish
- National Institute for Health Research [NIHR-RP-02-12-011] Funding Source: researchfish
- National Institutes of Health Research (NIHR) [NIHR-RP-02-12-011] Funding Source: National Institutes of Health Research (NIHR)
Ask authors/readers for more resources
Barrett's esophagus (BE) and gastroesophageal reflux disease are the strongest risk factors for esophageal adenocarcinoma. To reduce the clinical impact of this disease, endoscopic screening to detect BE has been proposed and nonendoscopic diagnostic techniques are under investigation. Because screening would result in new diagnoses of BE and additional costs related to endoscopic surveillance, novel tools for risk stratification are also warranted. Dysplasia is the gold standard for risk stratification. Molecular biomarkers may provide a more objective and reproducible estimation of the individual risk, and further prospective studies are required as a prelude to introducing biomarkers into routine clinical practice.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available